Welcome to our dedicated page for 23Andme Holding news (Ticker: ME), a resource for investors and traders seeking the latest updates and insights on 23Andme Holding stock.
23andMe Holding Co. reported developments tied to its human genetics, consumer health, and research businesses, including new 23andMe+ Premium genetic reports, lab-test offerings, and Discover23 research access for biopharma collaborators. Company updates also covered its proprietary genetic and health-information database, consented research participation, and privacy policies governing customer data.
Recent corporate news focused on liquidity, discontinued therapeutics operations, strategic alternatives, board and leadership changes, and Chapter 11 proceedings involving a court-supervised asset sale process. These updates frame the company’s transition from an operating consumer genetics business into a restructuring and corporate-status story.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
23andMe Holding Co. (Nasdaq: ME) announced promising results from the Phase 1 trial of its investigational antibody 23ME-00610, aimed at treating advanced solid malignancies. The data revealed a favorable safety and tolerability profile, with no dose-limiting toxicities reported. A recommended dose of 1400 mg has been selected for the ongoing Phase 2a study, evaluating the anti-tumor activity of 23ME-00610. This study will assess various cancer types including clear cell renal cell carcinoma and small cell lung cancer. The drug targets CD200R1, crucial for immune response against tumors.
Clinical results will be presented at the AACR Annual Meeting on April 18, 2023, where further details on efficacy and pharmacokinetics are expected to bolster investor confidence in 23andMe's therapeutic pipeline.
23andMe Holding Co. (Nasdaq: ME) has partnered with Morehouse School of Medicine (MSM) and the Sickle Cell Foundation of Georgia to launch a Sickle Cell Carrier Status Awareness program. This initiative aims to raise awareness of sickle cell disease and provide free Health+Ancestry DNA testing kits to MSM students, faculty, and staff. Participants will receive counseling about their results, which include a Carrier Status report for sickle cell anemia. Notably, around 300 million people globally and 1 in 13 Black or African Americans are carriers of sickle cell anemia. The collaboration seeks to improve genetic equity, especially among underrepresented communities, and educate individuals on their genetic health risks, potentially impacting future research and product development.